Who are ceftriaxone and azithromycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amoxicillin, Clarithromycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ceftriaxone-and-azithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ceftriaxone and azithromycin — Competitive Intelligence Brief

ceftriaxone and azithromycin (ceftriaxone and azithromycin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic and macrolide antibiotic combination. Area: Infectious Disease.

marketed Beta-lactam antibiotic and macrolide antibiotic combination Bacterial cell wall (ceftriaxone) and bacterial 50S ribosome (azithromycin) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ceftriaxone and azithromycin (ceftriaxone and azithromycin) — Sheba Medical Center. This combination uses a third-generation cephalosporin to inhibit bacterial cell wall synthesis and a macrolide antibiotic to inhibit bacterial protein synthesis, providing broad-spectrum coverage against respiratory pathogens.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ceftriaxone and azithromycin TARGET	ceftriaxone and azithromycin	Sheba Medical Center	marketed	Beta-lactam antibiotic and macrolide antibiotic combination	Bacterial cell wall (ceftriaxone) and bacterial 50S ribosome (azithromycin)
Amoxicillin, Clarithromycin	Amoxicillin, Clarithromycin	Mackay Memorial Hospital	marketed	Beta-lactam antibiotic and macrolide antibiotic combination	Bacterial cell wall (amoxicillin); bacterial 50S ribosome (clarithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic and macrolide antibiotic combination class)

Mackay Memorial Hospital · 1 drug in this class
Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ceftriaxone and azithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftriaxone-and-azithromycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab